Voyager Therapeutics, Inc. VYGR
2.68
(0.12)
(4.29%)
as of 25 Sep
- Market cap
- $172.5M
- P/E
- 0.0×
Follow VYGR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (54.09%) | (52.26%) | (48.29%) | (46.09%) |
+8 more TTM periods Free account |
|
| (41.45%) | (40.74%) | (37.10%) | (35.50%) | ||
ROIC |
(192.55%) | (247.40%) | 0.00% | (804.33%) | |
Return on Tangible Assets |
(89.97%) | (82.29%) | (63.25%) | (64.23%) | |
Average Days of Receivables |
33.41 | 16.45 | 17.29 | 47.05 | |
Free Cash Flow per Share |
(2.01) | (2.18) | (2.30) | (2.02) | |
Free Cash Flow |
(121.42) | (129.94) | (135.06) | (118.86) | |
Capital Expenditures |
(0.85) | (1.95) | (2.60) | (2.12) | |
Piotroski F-Score |
2.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(44.54%) | (40.61%) | (33.75%) | (27.23%) | |
Accounts Receivable Turnover |
12.14 | 19.44 | 19.73 | 2.64 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
343.77% | 350.06% | 333.57% | 428.87% | |
Selling, General and Administrative Expense of Revenue |
96.31% | 99.10% | 92.99% | 118.86% | |
Share Based Compensation of Revenue |
34.54% | 37.27% | 36.63% | 47.91% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 1.10 | 1.11 | 0.92 | |
Depreciation/Fixed assets |
0.18 | 0.13 | 0.08 | 0.01 | |
Capex/Depreciation |
(0.42) | (1.19) | (2.39) | (32.20) | |
Revenue per Share |
0.57 | 0.61 | 0.69 | 0.53 | |
Operating CF per Share |
(1.99) | (2.15) | (2.26) | (1.99) | |
Capex per Share |
(0.01) | (0.03) | (0.04) | (0.04) | |
Capex to Sales |
0.02 | 0.05 | 0.06 | 0.07 | |
Net Profit Margin |
(312.63%) | (319.61%) | (296.53%) | (404.85%) |
Columns are period end dates